23 results
Thumbnail

D1.349 - Early Diagnosis of WHIM Syndrome in Infancy: A Case with a De Novo CXCR4 Mutation

Thumbnail

D1.348 - Retrospective Evaluation of Laboratory and Clinical Characteristics of Pediatric Patients Diagnosed with IgG Subclass Deficiency and Receiving Intravenous Immunoglobulin Replacement Therapy

Thumbnail

D1.350 - Selective IgA deficiency and its association with allergic and autoimmune diseases

Thumbnail

D1.351 - Chronic urticaria and autoimmunity: clinical, laboratory and molecular associations

Thumbnail

D1.353 - A Rare Cause of Recurrent Infections: SIFD Syndrome

Thumbnail

D1.354 - Possible Association of a MYOF Loss-of-Function Variant With Recurrent Angioedema: Overlap Between Chronic Spontaneous Urticaria and Normal-C1 Hereditary Angioedema? A Case Report

Thumbnail

D1.355 - Familial Recurrent Angioedema with Normal C1-Inhibitor: A Clinical Case Series Suggestive of HAE with Normal C1-INH

Thumbnail

D1.356 - Atypical association of anti-EJ and anti-RNA polymerase III antibodies in a patient referred for interstitial lung disease

Thumbnail

D1.357 - Atypical case of common variable immune deficiency with granulomatous lymphocytic interstitial lung disease

Thumbnail

D1.363 - Long-Acting Prophylactic Injection BW-20805: Remarkable and Sustained HAE Attack Reduction — Updated Analysis from an Ongoing Phase 2 Study

Thumbnail

D2.471 - Efficacy of omalizumab in the treatment of chronic spontaneous urticaria in children

Thumbnail

D2.473 - Omalizumab as adjuvant therapy in drug desensitization to chemotherapy- a single Center experience

Thumbnail

D2.475 - Treatment delay and likelihood of remission on omalizumab in chronic spontaneous urticaria: a real-world observational study

Thumbnail

D2.464 - Stapokibart (anti–IL-4Rα monoclonal antibody) across type 2 inflammatory diseases in routine practice: a three-case series of severe atopic dermatitis, chronic urticaria with rhinosinusitis, and immune-related bullous pemphigoid

Thumbnail

D2.465 - Omalizumab Enhances Safety and Supports Completion of Oral Immunotherapy in High-Risk Patients

Thumbnail

D2.466 - More options for the treatment of Chronic Spontaneous Urticaria: Tezepelumab

Thumbnail

D2.467 - Management of Netherton syndrome and hereditary angioedema with concurrent biologic therapy: a novel case

Thumbnail

D2.468 - Real-world effectiveness and safety of dupilumab in pediatric atopic dermatitis: a retrospective cohort study

Thumbnail

D2.469 - Pre-switch perceptions of omalizumab biosimilar prefilled pen in pediatric allergy: a cross-sectional survey

Thumbnail

D2.470 - Potential Clinical and Laboratory Biomarkers for Predicting Omalizumab Response in Chronic Spontaneous Urticaria